Comparison
Both are next-generation weight management compounds in late-stage clinical development, with reported weight loss substantially exceeding approved GLP-1 agents. They arrive at similar efficacy outcomes through different mechanistic approaches: retatrutide via triple incretin/glucagon receptor agonism, CagriSema via co-formulation of a GLP-1 agonist with a long-acting amylin analogue.
Neither compound is approved as of the knowledge cutoff. Both remain in Phase 2/3 clinical trials. All use outside approved trials is investigational.
| Attribute | Retatrutide | CagriSema |
|---|---|---|
| Developer | Eli Lilly (LY3437943) | Novo Nordisk (co-formulation of semaglutide + cagrilintide) |
| Class | Triple agonist (GLP-1 / GIP / glucagon receptors) | GLP-1 agonist + long-acting amylin analogue |
| Components | Single molecule with triple receptor activity | Semaglutide 2.4 mg + cagrilintide 2.4 mg (fixed co-formulation) |
| Mechanism | Simultaneously activates GLP-1, GIP, and glucagon receptors; glucagon agonism increases energy expenditure | GLP-1 receptor agonism (semaglutide) combined with amylin receptor agonism (cagrilintide); complementary satiety pathways |
| Half-life | ~6 days | Semaglutide ~7 days; cagrilintide ~7 days (both designed for weekly dosing) |
| Dosing | 2–12 mg/week SubQ (titration-based) | 2.4 mg/2.4 mg weekly SubQ (fixed dose co-formulation) |
| Reported weight loss | ~24% body weight (Phase 2 data) | ~22–25% body weight (Phase 3 REDEFINE trials, preliminary data) |
| Approval status | Not approved; Phase 2/3 development | Not approved; Phase 3 development (REDEFINE programme) |
The most fundamental difference is the biological pathway each compound uses to achieve its effects. Retatrutide is a single engineered molecule that simultaneously activates three receptors: GLP-1, GIP, and glucagon. The glucagon component is central to its differentiated profile, as glucagon receptor agonism raises basal metabolic rate and increases energy expenditure, adding an output-side mechanism to complement the intake-side effects of GLP-1 and GIP agonism. This triple-receptor approach attempts to address both caloric intake and energy expenditure within a single molecule.
CagriSema takes a different route: it combines two established components (semaglutide, a proven GLP-1 agonist, and cagrilintide, a long-acting amylin analogue) in a fixed co-formulation. Amylin is a pancreatic hormone co-secreted with insulin that suppresses glucagon, slows gastric emptying, and promotes satiety through central nervous system pathways distinct from GLP-1. By adding amylin receptor agonism to GLP-1 receptor agonism, CagriSema engages two satiety pathways that are physiologically independent, potentially producing greater appetite suppression than either mechanism alone.
In terms of reported efficacy, both compounds appear to achieve weight loss in the 22–25% range in their respective trial programmes, which represents a significant step beyond tirzepatide (~20%) and semaglutide mono-therapy (~15%). Direct comparison between the two requires caution, as their trial designs, populations, and follow-up durations differ, and no head-to-head trial data is available.
Retatrutide activates three receptor systems:
CagriSema combines two complementary mechanisms:
Research has investigated both compounds primarily for their potential role in obesity management and metabolic health. Given that both are in late-stage development, research to date has focused mainly on weight reduction and glycaemic outcomes. Broader indication investigation (cardiovascular outcomes, organ-specific metabolic effects) is anticipated but not yet fully published for either compound.
CagriSema's use of semaglutide as a component means its GLP-1 pathway effects benefit from the extensive existing semaglutide literature, including cardiovascular and renal outcomes data from semaglutide studies. However, those outcomes cannot be extrapolated to CagriSema without dedicated trial data on the combination.
Reported side effects in research and anecdotal accounts for both compounds include GI effects common to the GLP-1 class (nausea, vomiting, diarrhoea, constipation). Retatrutide's glucagon component may affect GI motility differently from pure GLP-1/GIP agents. CagriSema phase 3 data has reported nausea rates broadly consistent with GLP-1 agents at therapeutic doses. Both require slow titration. Neither compound has post-approval safety data, as both remain in clinical development.
Retatrutide and CagriSema would not typically be co-administered in research. CagriSema already contains semaglutide, a GLP-1 agonist, and retatrutide is also a GLP-1 agonist: combining them would stack GLP-1 pathway agents without established mechanistic rationale. The most informative comparison is between them as alternative approaches to next-generation obesity pharmacotherapy rather than as complementary agents.
Research contexts focused on metabolic rate and energy expenditure as mechanisms of interest may favour retatrutide, given its glucagon receptor component, which adds a direct metabolic rate-increasing pathway absent from both amylin-based approaches and current approved GLP-1 agents.
Research contexts where amylin pathway biology is the focus of investigation, or where a combination of established (semaglutide) and novel (cagrilintide) components provides a more interpretable mechanistic framework, may favour CagriSema. Its co-formulation of a well-characterised GLP-1 agent with a novel amylin analogue allows clearer attribution of effects.
Both compounds remain investigational, and access outside clinical trials is limited. Researchers considering either compound should account for the preliminary nature of the available efficacy and safety data.
Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk. Amylin is a 37-amino-acid peptide co-secreted with insulin by pancreatic beta cells, with roles in satiety, gastric emptying, and glucagon suppression. Native amylin has a very short half-life; cagrilintide was engineered for once-weekly subcutaneous administration, matching the dosing frequency of semaglutide to allow co-formulation in CagriSema.
Glucagon receptor agonism does raise hepatic glucose output, which would ordinarily be counterproductive. In retatrutide, this effect is offset by simultaneous potent GLP-1 and GIP receptor agonism, which strongly stimulates glucose-dependent insulin secretion. The net effect on blood glucose is therefore favourable. The beneficial contribution of glucagon agonism in this context is increased energy expenditure and basal metabolic rate, which adds an output-side mechanism to the intake-side effects of the other two receptor targets.
Phase 2 retatrutide data reported approximately 24% mean weight loss at 48 weeks. Preliminary Phase 3 CagriSema data has reported approximately 22–25% mean weight loss. Both compounds appear to achieve similar maximum weight loss depth, though cross-trial comparisons are limited by differences in patient populations, trial duration, and dose escalation protocols. No head-to-head comparative trial data is yet available.
Both compounds are in Phase 3 development as of the knowledge cutoff (mid-2025). Regulatory submissions and approvals, if trial data are positive, would be expected in the 2025–2027 timeframe. This timeline is subject to trial outcomes and regulatory review processes, and neither compound has a confirmed approval date.